

NeXT Dx™ Test Gene List

Cancer-related Genes

Single nucleotide variants, small insertions and deletions, copy number alterations, and gene fusions involving the genes below may be reported in the test.

ABCB1 [†]	CAMTA1 [†]	CSF1R [†]	EWSR1 [†]	GATA1 [†]	LIG4	MUTYH [†]	PDGFA	PTPN11 [†]	SDHA [*]	TMPRSS2 [†]
ABL1 [†]	CBFB [†]	CSF3R [†]	EXO1	GATA2 ^{**}	LRP1B	MYC [†]	PDGFB [†]	PVRL4 [†]	SDHAF2 [*]	TNFRSF4 [†]
AKAP9 [†]	CBL [†]	CTAG2 [†]	EZH2 [†]	GEN1	MAGEA3 [†]	MYCL	PDGFRA ^{**}	RAD21 [†]	SDHB ^{**}	TNFRSF8 [†]
AKT1 [†]	CCNA1	CTDNEP1	EZHIP [†]	GLI2 [†]	MAGEA4 [†]	MYCN [†]	PDGFRB [†]	RAD50 ^{**}	SDHC ^{**}	TNFRSF10B
AKT2 [†]	CCNA2	CTLA4 [†]	FAM175A	GNA11 [†]	MAML1	MYD88 [†]	PGR [†]	RAD51 [†]	SDHD ^{**}	TP53 ^{**}
AKT3 [†]	CCNB1	CTNNA1	FAN1	GNAQ [†]	MAP2K1 [†]	MYH11 [†]	PHF1 [†]	RAD51B [†]	SETBP1 [†]	TSC1 ^{**}
ALK ^{**}	CCNB2	CTNNA2	FANCA [†]	GNAS [†]	MAP2K2 [†]	MYOD1 [†]	PIK3CA ^{**}	RAD51C ^{**}	SETD2	TSC2 ^{**}
APC ^{**}	CCNB3 [†]	CTNNA3	FANCB [†]	GPNMB [†]	MAP2K4 [†]	NAB2 [†]	PIK3CB [†]	RAD51D ^{**}	SF3B1 [†]	TYRO3
APOBEC3B	CCND1 [†]	CTNNB1 [†]	FANCC [†]	H3F3A	MAP3K1 [†]	NBN	PIK3CD [†]	RAD52	SHFM1	U2AF1 [†]
AR [†]	CCND2 [†]	CUX1 [†]	FANCD2 [†]	HDAC1	MAPK1 [†]	NCSTN	PIK3CG [†]	RAD54B	SHH [†]	USH2A
ARAF [†]	CCND3 [†]	DDR2 [†]	FANCE [†]	HDAC2	MAPK11	NF1 ^{**}	PIK3R1 [†]	RAD54L	SLX4 [†]	VEGFA [†]
AREG [†]	CCNE1 [†]	DDX3X	FANCF [†]	HEY1 [†]	MAPK3	NF2 ^{**}	PIK3R2	RAF1 [†]	SMAD4 ^{**}	VEGFB [†]
ARID1A [†]	CCNE2	DEK [†]	FANCG [†]	HNF1A [†]	MAX [*]	NFE2L2 [†]	PML [†]	RARA [†]	SMARCA4 [†]	VEGFC
ARID1B	CD274 [†]	DDK1 [†]	FANCI [†]	HRAS [†]	MBTD1 [†]	NKX2-1 [†]	PMS1	RB1 ^{**}	SMARCB1 [†]	VGLL2 [†]
ARID2	CD276 [†]	DLL3 [†]	FANCL [†]	HSP90AA1 [†]	MCL1 [†]	NOTCH1 [†]	PMS2 ^{**}	RBBP8	SMC1A [†]	VHL ^{**}
ASXL1 [†]	CD40 [†]	DLL4	FANCM [†]	IDH1 [†]	MCPH1	NOTCH2 [†]	POLD1 [†]	RBM15 [†]	SMC3 [†]	WEE1 [†]
ATM ^{**}	CDH1 ^{**}	DNMT3A [†]	FBXW7 [†]	IDH2 [†]	MDC1	NOTCH3 [†]	POLD2	RECQL4	SMO [†]	WRN
ATR [†]	CDH3 [†]	DOT1L	FCER2 [†]	IGF1R [†]	MDM2 [†]	NOTCH4	POLE ^{**}	RELA [†]	SRC [†]	WT1 ^{**}
ATRX [†]	CDK1	EED	FGF2 [†]	IKBKE	MDM4 [†]	NPAP1	POLQ	RET ^{**}	SRSF2 [†]	WWTR1 [†]
AURKA [†]	CDK2	EGFR ^{**}	FGF4	IKZF1 [†]	MECOM [†]	NPM1 [†]	PPM1D	RFC1	SS18 [†]	XPO1 [†]
AXL [†]	CDK4 ^{**}	EIF1AX	FGF19 [†]	IL2RA [†]	MEN1 ^{**}	NR4A3 [†]	PPP2R1A	RFC2	SSBP1	XRCC1 [†]
BAP1 ^{**}	CDK6 [†]	EML4 [†]	FGFR1 [†]	JAG1	MERTK	NRAS [†]	PPP2R2A	RFC3	STAG2 [†]	XRCC2
BARD1 [*]	CDK9 [†]	EP300 [†]	FGFR2 [†]	JAK1 [†]	MET ^{**}	NRG1 [†]	PRAME [†]	RFC4	STAT3 [†]	XRCC3
BCL2 [†]	CDK12	EPCAM [†]	FGFR3 [†]	JAK2 [†]	MGAM	NTRK1 [†]	PRKACA [†]	RFC5	STAT5B [†]	XRCC4
BCL6 [†]	CDKN1A [†]	EPHA2	FGFR4 [†]	JAK3 [†]	MKL1 [†]	NTRK2 [†]	PRKCA [†]	RHEB	STAT6 [†]	XRCC5
BCOR [†]	CDKN1B ^{**}	ERBB2 [†]	FH ^{**}	KDM5C	MLH1 ^{**}	NTRK3 [†]	PRKCB [†]	RICTOR [†]	STK11 ^{**}	XRCC6
BCORL1 [†]	CDKN2A ^{**}	ERBB3 [†]	FIGF	KDM6A [†]	MLH3	NUP214 [†]	PRKCD [†]	ROS1 [†]	SUFU [*]	YAP1 [†]
BCR [†]	CDKN2B [†]	ERBB4 [†]	FLCN ^{**}	KDR [†]	MLLT3 [†]	NUTM2A [†]	PRKCE [†]	RPA1	SULT1A1 [†]	YES1 [†]
BLM	CDKN2C	ERCC1	FLT1 [†]	KEAP1	MPL [†]	OTX2	PRKCG [†]	RPA2	SUZ12 [†]	YWHAE [†]
BRAF [†]	CEBPA ^{**}	ERCC2	FLT3 [†]	KIT ^{**}	MRE11A ^{**}	PALB2 ^{**}	PRKCI [†]	RPA3	SYK [†]	ZMYM3
BRCA1 ^{**}	CHEK1 [†]	ERCC3	FLT4 [†]	KLB [†]	MS4A1 [†]	PARP1 [†]	PRKCC [†]	RPA4	TEK	ZRSR2 [†]
BRCA2 ^{**}	CHEK2 ^{**}	ERCC4	FOLR1 [†]	KMT2A [†]	MSH2 ^{**}	PARP2	PRKCZ [†]	RPN1 [†]	TERT ^{**}	
BRD4 [†]	CIC [†]	ERCC5	FOXL2 [†]	KMT2C	MSH3	PAX3 [†]	PRKDC	RPTOR	TET2 [†]	
BRIP1 ^{**}	CREBBP [†]	ERCC6	FOXO1 [†]	KMT2D	MSH6 ^{**}	PBRM1	PSCA [†]	RTEL1 [*]	TFE3 [†]	
BTK [†]	CRKL [†]	ESR1 [†]	FRK	KRAS [†]	MSLN [†]	PCNA	PTCH1 ^{**}	RUNX1 ^{**}	TGFB [†]	
C11orf30	CRLF2 [†]	ESR2 [†]	FUS [†]	LAG3 [†]	MST1R	PDCD1 [†]	PTEN ^{**}	RUNX1T1 [†]	TGFB [†]	
CALR [†]	CRTC1 [†]	ETV6 ^{**}	FYN [†]	LIG3	MTOR [†]	PDCD1LG2 [†]	PTK2 [†]	RYR1	TMEM127 [*]	

* Represents genes in which likely pathogenic/pathogenic germline variants will be reported, in addition to somatic variants, as incidental findings

† Represents fusion genes



Personalis, Inc.

6600 Dumbarton Cir
Fremont CA 94555
+1 855-373-7978
www.personalis.com
clientservices@personalis.com

Personalis NeXT Dx™ Test: This laboratory developed test (LDT) will be performed in a CLIA/CAP accredited laboratory. The test was developed and its performance characteristics determined by the Personalis Clinical Laboratory. It has not been cleared or approved by the United States Food and Drug Administration (FDA). The Personalis Clinical Laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.

© 2023 Personalis, Inc. All rights reserved. Personalis®, Personalis NeXT Dx™ Test are trademarks of Personalis, Inc.



DOC-000611(C)